Rhythm Pharmaceuticals, Inc.
RYTM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001649904
In the last 90 days, Rhythm Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 307 institutions reported holding it in 13F filings for Q2 2026, worth $8.55B in total; Duquesne Family Office is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:19 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $196.5M (103.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 9, 2026 | Jan 10, 2025 | Feb 22, 2024 | Mar 1, 2023 | Mar 1, 2022 |
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.15M |
| Cost of revenue | $19.5M | $13.4M | $9.30M | $2.13M | $599.0K |
| Research and development | $167.3M | $238.0M | $135.0M | $108.6M | $104.1M |
| Selling, general and administrative | $194.9M | $144.3M | $117.5M | $92.0M | $68.5M |
| Operating income | -$192.0M | -$265.5M | -$184.4M | -$179.2M | -$170.1M |
| Interest expense | – | – | $13.9M | $5.20M | – |
| Income tax | $497.0K | $346.0K | $564.0K | – | – |
| Net income | -$196.5M | -$260.6M | -$184.7M | -$181.1M | -$69.6M |
| EPS, basic | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
| EPS, diluted | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
| Weighted shares, basic | 65.0M | 61.0M | 57.7M | 52.1M | 49.6M |
| Weighted shares, diluted | 65.0M | 61.0M | 57.7M | 52.1M | 49.6M |
| Margins and growth | |||||
| Operating margin | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% |
| Net margin | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% |
| Revenue growth, year over year | +45.8% | +68.1% | +227.6% | +649.5% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025! | FY2024! | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 9, 2026 | Jan 10, 2025 | Feb 22, 2024 | Mar 1, 2023 | Mar 1, 2022 |
| Cash and equivalents | $54.3M | $89.1M | $60.1M | $127.7M | $59.2M |
| Short-term investments | $334.6M | $231.4M | $215.8M | $205.6M | $235.6M |
| Accounts receivable | $26.1M | $18.5M | $14.9M | $6.22M | $1.02M |
| Inventory | $25.8M | $18.7M | $8.62M | $2.92M | $111.0K |
| Total current assets | $466.9M | $374.2M | $308.3M | $354.2M | $308.4M |
| Property, plant and equipment | $1.10M | $632.0K | $1.34M | $2.20M | $2.81M |
| Intangible assets | $5.32M | $6.17M | $7.03M | $7.88M | $4.66M |
| Total assets | $480.2M | $392.3M | $332.7M | $382.5M | $329.5M |
| Accounts payable | $13.9M | $12.3M | $4.88M | $4.80M | $5.74M |
| Short-term debt | $7.30M | $1.54M | – | – | – |
| Total current liabilities | $105.9M | $115.5M | $55.2M | $39.8M | $43.4M |
| Long-term debt | $100.9M | $108.3M | – | – | – |
| Total liabilities | $210.2M | $227.7M | $163.0M | $118.2M | $45.4M |
| Shareholders' equity | $139.1M | $21.7M | $169.8M | $264.3M | $284.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 9, 2026 | Jan 10, 2025 | Feb 22, 2024 | Mar 1, 2023 | Mar 1, 2022 |
| Operating cash flow | -$115.7M | -$113.9M | -$136.2M | -$173.4M | -$146.0M |
| Capital expenditures | $953.0K | – | $47.0K | $281.0K | $434.0K |
| Free cash flow | -$116.6M | – | -$136.2M | -$173.7M | -$146.4M |
| Depreciation and amortization | $500.0K | $710.0K | $903.0K | $896.0K | $816.0K |
| Stock-based compensation | $66.8M | $39.7M | $32.6M | $19.8M | $20.8M |
| Investing cash flow | -$137.2M | -$48.2M | -$5.67M | $28.0M | -$62.2M |
| Financing cash flow | $218.0M | $191.2M | $74.4M | $213.8M | $166.5M |
| Net change in cash | -$34.8M | $29.2M | -$67.6M | $68.4M | -$41.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 35.2% | 30.5% | 42.0% | 83.9% | 659.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 69.3M | +3.9% | SEC |
| Aug 1, 2026 | 68.9M | +3.7% | SEC |
| May 1, 2026 | 68.5M | +7.7% | SEC |
| Feb 24, 2026 | 68.3M | +8.0% | SEC |
| Oct 31, 2025 | 66.7M | +8.6% | SEC |
| Aug 1, 2025 | 66.4M | +8.6% | SEC |
| Apr 30, 2025 | 63.6M | +4.3% | SEC |
| Feb 24, 2025 | 63.2M | +5.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.